Metabolism of drugs of abuse by cytochromes P450

Addiction Biology

Volumn 4, Issue 3, 1999, Pages 283-301

  Cho, Arthur K ^a   Narimatsu, Shizuo ^b   Kumagai, Yoshito ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OKAYAMA UNIVERSITY   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; ILLICIT DRUG; XENOBIOTIC AGENT;

DRUG ELIMINATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SPECIFICITY; GENETICS; LIPID SOLUBILITY; PRIORITY JOURNAL; REVIEW;

EID: 0032839602     PISSN: 13556215     EISSN: None     Source Type: Journal    
DOI: 10.1080/13556219971498     Document Type: Review

References (155)

1. Nebert DW, Nelson DR, Adesnik M, et al. The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA 1989;8:1-13.
2. Guengerich FP. Cytochromes P450 of human liver. Classification and activity profiles of the major enzymes. In: Pacifici GM, Fracchia GN, editors. Advances in drug metabolism in man. Belgium: Office for Official Publications of the European Communities; 1995, pp. 181-231.
3. Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42.
4. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997;29:413-580.
5. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
6. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Ann Rev Pharmacol Toxicol 1998;38:389-430.
7. Bertilsson, L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209.
8. Eckhardt K, Li S, Ammon S, et al. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998;76:27-33.
9. Tyndale RF, Droll K, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997;7:375-9.
10. Stubbins MJ, Harries LW, Smith G, et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996;6:429-39.
11. Brzezinski MR, Spink BJ, Dean RA, et al. Human liver carboxylesterase hCE-1: binding specificity for cocaine, heroin, and their metabolities and analogs. Drug Metab Disposition 1997;25: 1089-96.
12. Pindel EV, Kedishvili NY, Abraham TR, et al. Purification and cloning of a broad substrate specificity human liver carboxylesterase that catalyzes the hydrolysis of cocaine and heroin. J Biol Chem 1997;272:14769-75.
13. Stewart DJ, Inaba T, Lucassen M, et al. Cocaine metabolism: cocaine and norcocaine hydrolysis by liver and serum esterases. Clinl Pharmacol Ther 1979;25:464-8.
14. Lawton MP, Cashman JR, Cresteil T, et al. A nomenclature for the mammalian flavin-containing monooxygenase gene family based on amino acid sequence identities. Arch Biochem Biophys 1994;308:254-7.
15. Kanel GC, Cassidy W, Shuster L, et al. Cocaine-induced liver cell injury, comparison of morphological features in man and in experimental models. Hepatology 1990;11:646-51.
16. Kloss MW, Rosen GM, Rauckman EJ. N-demethylation of cocaine to norcocaine. Evidence for participation by cytochrome P450 and FAD-containing monooxygenase. Mol Pharmacol 1983;23:482-5.
17. Boelsterli UA, Lanzotti A, Goldlin C, et al. Identification of cytochrome P-45011B1 as a cocainebioactivation isoform in rat hepatic microsomes and in cultured rat hepatocytes. Drug Metab Disposition 1992;20:96-101.
18. Pellinen P, Honkakoski P, Stenback F, et al. Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochromc P450 3A inhibitors. Eur J Pharmacol 1994;270:35-43.
19. Poet TS, McQueen CA, Halpert JR. Participation of cytochromes P4502B and P4503A in cocaine toxicity in rat hepatocytes. Drug Metab Disposition 1996;24:74-80.
20. LeDuc BW, Sinclair PR, Shuster L, et al. Norcocaine and N-hydroxynorcocaine formation in human liver microsomes: role of cytochrome P-450 3A4. Pharmacology 1993;46:294-300.
21. Shuster L, Casey E, Welankiwar SS. Metabolism of cocaine and norcocaine to N-hydroxynorcocaine. Biochem Pharmacol 1983; 32:3045-51.
22. Thompson ML, Shuster L, Shaw K. Cocaine-induced hepatic necrosis in mice: the role of cocaine metabolism. Biochem Pharmacol 1979; 28:2389-95.
23. Roberts SM, Harbison RD, James RC. Human microsomal N-oxidative metabolism of cocaine. Drug Metab Disposition 1991;19:1046-51.
24. Jatlow P, Elsworth JD, Bradberry CW, et al. Cocaethylene: a neuropharmacologically active metabolite associated with concurrent cocaine-ethanol ingestion. Life Sci 1991;48:1787-94.
25. Andrews P. Cocaethylene toxicity. J Addict Dis 1997;16:75-84.
26. Dean KA, Christian CD, Sample RHB, et al. Human liver cocaine esterases: ethanol-mediated formation of ethylcocaine. FASEB J 1991;5: 2735-9.
27. Kamendulis LM, Brzezinski MR, Pindel EV, et al. Metabolism of cocaine and heroin is regulated by the same liver carboxylesterase. J Pharmacol Exp Ther 1996;279:713-17.
28. Bailey D. Cocaine and cocaethylene binding in human serum. Am J Clin Pathol 1995;180-6.
29. Perez-Reyes M, Jeffcoat AR, Myers M, et al. Comparison in humans of the potency and pharmacokinetics of intravenously injected cocaethylene and cocaine. Psychopharmacology (Berl) 1994;116:425-35.
30. Dring L, Smith R, Williams R. The metabolic fate of amphetamine in man and other species. Biochem J 1970;116:425-35.
31. Law MY, Moody DE. Urinary excretion of amphetamine and 4′-hydroxyamphetamine by Sprague-Dawley and dark Agouti rats. Life Sci 1994;54:1073-9.
32. Al-Dabbagh SG, Idle JR, Smith RL. Animal modelling of human polymorphic drug oxidation - the metabolism of debrisoquine and phenacetin in rat inbred strains. J Pharm Pharmacol 1981;33: 161-4.
33. Eichelbaum M, Spannbrucker N, Steincke B, et al. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 1979;16:183-7.
34. Gonzalez FJ. The CYP2D subfamily. In: Ioannides C, editor. Cytochromes P450: Metabolic and Toxicological Aspects. New York: CRP Press; 1996; 183-210.
35. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977,2:584-6.
36. Crewe H, Lennard M, Tucker G, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992:34:262-5.
37. Yamada H, Honda S, Oguri K, et al. A rabbit liver constitutive form of cytochrome P450 responsible for amphetamine deamination. Arch Biochem Biophys 1989;273:26-33.
38. Guengerich FP. Comparison of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem Biol Interact 1997;106: 161-82.
39. Florence VM, DiStefano EW, Sum CY, et al. The metabolism of R-(-)-amphetamine by rabbit liver microsomes: initial products. Drug Metab Disposition 1982:10:312-15.
40. Jonsson KH, Lindeke B. Cytochrome P-455nm complex formation in the metabolism of phenylalkylamines. XII. Enantioselectivity and temperature dependence in microsomes and reconstituted cytochrome P-450 systems from rat liver. Chirality 1992;4:469-77.
41. Yamada H, Baba T, Hirata Y, et al. Studies on N-demethylation of methamphetamine by liver microsomes of guinea-pigs and rats: the role of flavin-containing mono-oxygenase and cytochrome P-450 systems. Xenobiotica 1984;14: 861-6.
42. Ziegler DM. Recent studies on the structure and function of multisubstrate flavin-containing monooxygenases. Ann Rev Pharmacol Toxicol 1993;33:179-99.
43. Baba T, Yamada H, Oguri K, et al. Participation of cytochrome P-450 isozymes in N-demethylation, N-hydroxylation and aromatic hydroxylation of methampheramine. Xenobiotica 1988;18: 475-84.
44. Yamada H, Yuno K, Oguri K, et al. Multiplicity of liver microsomal flavin-containing monooxygenase in the guinea pig: its purification and characterization. Arch Biochem Biophys 1990; 280:305-12.
45. Yamano S, Nhamburo PT, Aoyama T, et al. cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 1989;28:7340-8.
46. Miura M, Baba T, Yamazaki Y, et al. Characterization of cytochrome P450 2B6 in human liver microsomes. Drug Metab Disposition 1993;21: 1048-56.
47. Lin LY, Di Stefano EW, Schmitz DA, et al. Oxidation of methamphetamine and methylene-dioxymethamphetamine by CYP2D6. Drug Metab Disposition 1997;25:1059-64.
48. Lin LY, Kumagai Y, Hiratsuka A, et al. Cytochrome P4502D isozymes catalyze the 4-hydroxylation of methamphetamine enantiomers. Drug Metab Disposition 1995;23:610-14.
49. Marquardt GM, Distefano V, Ling LL. Metabolism of beta-3,4-methylenedioxyamphetamine in the rat. Biochem Pharmacol 1978;27: 1503-5.
50. Hiramatsu M, Kumagai Y, Linger SE, et al. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. J Pharmacol Exp Ther 1990;254:521-7.
51. Kumagai Y, Wickham KA, Schmitz DA, et al. Metabolism of methylenedioxyphenyl compounds by rabbit liver preparations: participation of different cytochrome P450 isozymes in the demethylenation reaction. Biochcm Pharmacol 1991;42:1061-7.
52. Kumagai Y, Lin LY, Philpot RM, et al. Regiochemical differences in cytochrome P450 isozymes responsible for the oxidation of methylenedioxyphenyl groups by rabbit liver. Mol Pharmacol 1992;42:695-702.
53. Wilkinson CF, Murray M, Marcus CB. Interactions of methylenedioxyphenyl compounds with cytochrome P-450 and effects on microsomal oxidation. Rev Biochem Toxicol 1984;6:27-63.
54. Lim HK, Foltz RL. In vivo and in vitro metabolism of 3,4- (methylenedioxy)methamphetamine in the rat: identification metabolites using an ion trap detector. Chem Res Toxicol 1988;1:370-8.
55. Cho AK, Hiramatsu M, Distefano EW, et al. Stereochemical differences in the metabolism of 3,4-methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis. Drug Metab Disposition 1990;18:686-91.
56. Kumagai Y, Lin LY, Schmitz DA, et al. Hydroxyl radical mediated demethylenation of (methylenedioxy)phenyl compounds. Chem Res Toxicol 1991;4:330-4.
57. Fonne-Pfister R, Bargetzi MJ, Meyer UA. MPTR, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufl, P450dbl) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 1987;148: 1144-50.
58. Niznik HB, Tyndale RF, Salee RF, et al. The dopamine transporter and cytochrome P450IId1 (debrisoquine 4-hydroxylase) in the brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. Arch Biochem Biophys 1990;276:424-32.
59. Tyndale RF, Sunahara R, Inaba T, et al. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991;40:63-8.
60. Komori M. A novel P450 expressed at the high level in rat brain. Biochem Biophys Res Commun 1993;196:721-8.
61. Kawashima K, Amano H, Fujimoto K, et al. Effect of repeated administration of KT3-671, a nonpeptide AT1 receptor antagonist, on diurnal variation in blood pressure, heart rate, and loco motor activity in stroke-prone spontaneously hypertensive rats as determined by radiotelemetry. J Cardiovasc Pharmacol 1996;27: 411-16.
62. Anandatheerthavarada HK, Shankar SK, Ravindranath V. Rat brain cytochrome P-450: catalytic, immunochemical properties and inducibility of multiple forms. Brain Res 1990;536:339-43.
63. Naslund B, Glaumann MAH, Warner M, et al. Cytochrome P-450 b and c in the rat brain and pituitary gland. Mol Pharmacol 1988;33:31-7.
64. Perrin R, Minn A, Ghersi-Egea J-F, et al. Distribution of cytochrome P450 activities towards alkoxyresorufin derivatives in rat brain regions, subcellular fractions and isolated cerebral microvessels. Biochem Pharmacol 1990;40:2145-51.
65. Strobel HW, Cattaneo E, Adesnik M, et al. Brain cytochrome P-450 are responsive to phenobarbital and tricyclic amines. Pharmacol Res 1989;21: 169-75.
66. Monks TJ, Lau SS. The pharmacology and toxicology of polyphenolic-glutathione conjugates. Ann Rev Pharmacol Toxicol 1998;38: 229-56.
67. Patel N, Kumagai Y, Unger SE, et al. Transformation of dopamine and alpha-methyldopamine by NG108 15 cells: formation of thiol adducts. Chem Res Toxicol 1991;4:421-6.
68. Walker TM, Davenport-Jones JE, Fox R, et al. The eftects of methylenedioxymethamphetamine and some of its metabolites on glutathione levels in rat brain spheroids in vivo. Br Toxicol Soc Abstr 1998.
69. Zhao Z, Castagnoli JR, N, Ricaurte GA, et al. Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4 (methylenedioxy)phenyl]propane [(methylenedioxy)methamphetamine]. Chem Res Toxicol 1992;5: 89-94.
70. Lim HK, Foltz RL. Ion trap tandem mass spectrometric evidence for the metabolism of 3,4-(methylenodioxy)methamphotamine to the potent neurotoxins 2,4,5-trihydroxymethamphetamine and 2,4,5-trihydroxyamphetamine. Chem Res Toxicol 1991;4:626-32.
71. Brady JF, Di Stefano EW, Cho AK. Spectral and inhibitory interactions of ( + / )-3,4-methylenedioxyamphetamine (MDA) and ( + / )-3, 4-methylenedioxymethamphetamine (MDMA) with rat hepatic microsomes. Life Sci 1986; 39:1457-64.
72. Mansuy D, Battioni JP, Chottard JL, et al. Preparation of porphyrin- iron carbene model for the cytochrome P-450 complexes obtained upon metabolic oxidation of the insecticide synergists of the 1,3-benzodioxole series. J Am Chem Soc 1979;101:3971-3.
73. Marcus CE, Murray M, Wilkinson CF. Spectral and inhibitory interactions of methylenedioxyphenyl and related compounds with purified isozymes of cytochrome P-450. Xenobiotica 1985;15:351-62.
74. Yamamoto I, Watanabe K, Narimatsu S, et al. Recent advances in the metabolism of cannabinoids. Int J Biochem Cell Biol 1995;8:741-6.
75. 1-tetrahydrocannabinol by hepatic microsomal oxygenase. Ann NY Acad Sci 1971;191:61-7.
76. Watanabe K, Hirahashi N, Narimatsu S, et al. Oxygenation mechanism of aldehyde to carboxylic acid catalyzed by a cytochrome P450 isozyme. J Biol Chom 1991;266:2709-11.
77. Watanabe K, Narimatsu S, Yamamoto I, et al. Hepatic microsomal oxygenation of aldehydes to carboxylic acids. Biochem Biophys Res Commun 1990,106:1308-12.
78. Watanabe K, Narimatsu S, Matsunaga T, et al. A cytochrome P450 isozyme having aldehyde oxygenase activity plays a major role in metabolizing cannabinoids by mouse hepatic microsomes. Biochem Pharmacol 1993;46:405-11.
79. 8-tetrahydrocannabinol, in mice. Drug Metab Disposition 1981;9: 261-4.
80. 9-THC. In: Agurell S, Deway WL, Willette RE, editors. The Cannabinoids: Chemical, Pharmacologie, and Therapeutic Aspects, Orlando, FL: Academic Press, 523-44.
81. 9-THC and seven monooxygenated metabolites correlated to the cataleptic effect in the mouse. Acta Pharmacol Toxicol 1980;47:308-17.
82. 8-tetrahydrocannabinol by mouse liver microsomes. Biochem Biophys Res Commun 1982;109:922-6.
83. Yamamoto I, Narimatsu S, Shimonishi T, et al. Epoxy metabolites formation from tetrahydrocannabinols and their further metabolism in the guinea pig. In: Harvey DJ, editor. Marihuana '84. Oxford, IRL Press, 1985;107-14.
84. 8-tetrahydrocannabinol. Chem Pharm Bull 1983;31: 1784-7.
85. 9- tetrahydrocannabinols by human liver microsomes. J Pharmacobio-Dynamics 1984;7:254-62.
86. 1-tetrahydrocannabinol. Drug Metab Disposition 1992;20: 241-6.
87. Richardson TH, Jung F, Griffin KJ, et al. A universal approach to the expression of human and rabbit cytochrome P450s of the 2C sub-family, Escherichia coli. Arch Biochem Biophys 1995;323:87-96.
88. Watanabe K, Matsunaga T, Yamamoto I, et al. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull 1995;18: 1138-41.
89. Narimatsu S, Watanabe K, Yamamoto I, et al. Inhibition of hepatic microsomal cytochrome P450 by cannabidiol in adult male rats. Chem Pharm Bull 1990;38:1365-8.
90. Narimatsu S, Watanahe K, Yamamoto I, et al. Mechanism for inhibitory effect of cannabidiol on microsomal testosterone oxidation in male rat liver. Drug Metab Disposition 1988;16:880-9.
91. Bornheim LM, Correia MA. Selective inactivation of mouse liver cytochrome P-450IIIA by cannabidiol. Mol Pharmacol 1990;38: 319-26.
92. Bornheim LM, Evanhart ET, Correia MA. Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol 1993;45: 1323-31.
93. Oguri K, Yoshimura H. Forensic toxicology of morphine and heroin. Jpn J Toxicol Environ Health (Eisei Kagaku) 1986;32:413-26.
94. Milne RW, Nation RL, Somogyi AA. The disposition of morphine and its 3- and 6-glucuronide metabolites in human and animals, and the importance of the metabolities to the pharmacological effects of morphine. Drug Metab Rev 1996;28:345-472.
95. Shimomura K, Kamata O, Ueki S, et al. Analgesic effects of morphine glucuronides, Tohoku J Exp Med 1971;105:45-52.
96. Osborne R, Joel S, Trew D, et al. Analgesic activity of 97. morphine 6-glucuronide. Lancet 1988;i: 823.
97. Frances B, Gout R, Monsarrat B, et al. Further evidence that morphine-6b-glucuronide is a more potent opioid agonist than morphine. J Pharmacol Exp Ther 1992;262:25-31.
98. Coffman BL, Rios GR, King CD, et al. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Disposition 1997;25:1-4.
99. Green MD, Belanger G, Hum DW, et al. Glucuronidation of opioids, carboxylic acid-containing drugs, and hydroxylated xenobiotics catalyzed by expressed monkey UDP-glucuronosyltransferase 2B9 protein. Drug Metab Disposition 1997;25: 1189-94.
100. Nagamatsu K, Kido Y, Terao T. Effects of morphinone on opiate receptor binding and morphine-elicited analgesia. Life Sci 1982;31:1451-7.
101. Yamano S, Kageura E, Ishida T, et al. Purification and characterization of guinea pig liver morphine 6-dehydrogenase. J Biol Chem 1985;260: 5259-64.
102. Yamano S, Takahashi A, Todaka T, et al. In vivo and in vitro formation of morphinone from morphine in rat. Xenobiotica 1997;27:645-56.
103. Rane A, Ask B. A conspicuous down-regulating effect of morphine on essential steroid hydroxylation reactions and certain drug N-demethylations. J Steroid Biochem Mol Biol 1992;41:91-8.
104. Ladona MG, Spalding DJM, Ekman I, et al. Human fetal and adult liver metabolism of ethylmorphine, relation to immunodetected cytochrome P450 PCN and interactions with important fetal corticosteroids. Biochem Pharmacol 1989;38:3147-55.
105. Liu Z, Mortimer O, Smith CAD, et al. Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism. Br J Clin Pharmacol 1995;39:77-80.
106. Way EL, Kemp JW, Young JM, et al. The pharmacologic effects of heroin in relationship to its rate of biotransformation. J Pharmacol Exp Ther 1960;129:144-54.
107. Lockridge O, Mottershaw-Jackson N, Eckerson HW, et al. Hydrolysis of diacetylmorphine (heroin) by human serum cholinesterase. J Pharmacol Exp The 1980;215:1-8.
108. Fujieda T, Enokiya K, Oguri K, et al. The contribution of 6-acetyl group to pharmacological effects of 6-acetylmorphine, an active metabolite of heroin. J Pharmacobio-Dynamics 1984;7: s-92.
109. 3-H-Morphine-6-beta-glucuronide binding to brain membranes and an MOR-1-transfected cell line. J Pharmacol Exp Ther 1997;282: 1291-7.
110. Yue QY, Svensson JO, Alm C, et al. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol 1989;28:639-45.
111. Mortimer O, Persson K, Ladona MG, et al. Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextrometorphan: relationship of the presence of immunoidentified cytochrome P450D1. Clin Pharmacol Ther 1990;47:27-35.
112. Caraco Y, Tateishi T, Guengerich FP, et al. Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity. Drug Metab Disposition, 1996;24:761-4.
113. Sladek NE, Chaplin MD, Mannering GJ. Sex-dependent differences in drug metabolism in the rat. IV. Effect of morphine administration. Drug Metab Disposition 1974;2:293-300.
114. Kato R. Characteristics and differences in the hepatic mixed function oxidases of different species. In: Schenkman JB, Kupfer D, editors. Hepatic Cytochrome P-450 Monooxygenase System. New York: Pergamon Press, 99-156.
115. Ho IK, Yamamoto I, Loh HH, et al. Effects of chronic administration of morphine on pentobarbital responses in the mouse. Biochem Pharmacol 1976;25:357-8.
116. Rane A, Liu ZR, Henderson CJ, et al. Divergent regulation of cytochrome P450 enzymes by morphine and pethidine. Mol Pharmacol 1995;47: 57-64.
117. Axelrod J. Possible mechanism of tolerance to narcotic drugs. Science 1956;124:263-4.
118. Yeh SY. Metabolism of meperidine in several animal species. J Pharm Sci 1984;73:1783-7.
119. Luttrell WE, Castle MC. Species differences in the hydrolysis of meperidine and its inhibition by organophosphate compounds. Fund Appl Toxicol 1988;11:323-32.
120. Eisendrath SJ, Goldman B, Douglas J, et al. Meperidine-induced delirium. Am J Psychiatry 1987;144:1062-5.
121. Goetting MG, Thirman MJ. Neurotoxicity of meperidine. Ann Emerg Med 1985,14:1007-9.
122. Kiff JV, Rice TL. Aleperidine-associated seizures in a child. Clin Pharm 1990;9:337-9.
123. Liller JW, Anderson HH. The effect of N-demethylation on certain pharmacologic actions of morphine, codeine, and meperidine in the mouse. J Pharmacol Exp Ther 1954;112: 191-6.
124. Mather LE, Meffin PJ. Clinical pharmacokinetics: pethidine. Clin Pharm 1978;3:352-68.
125. Danziger LH, Martin SJ, Blum RA. Central nervous system toxicity associated with meperidine use in hepatic disease. Pharmacotherapy 1994;14:235-8.
126. Stambaugh JK, Hemphill DM, Wainer IW, et al. A potentially toxic drug interaction between pethidine (meperidine) and phenobarbitone. Lancet 1977;1:398-9.
127. Pond SM, Kretschzmar KM. Effect of phenytoin on meperidine clearance and normeperidine formation. Clin Pharmacol Ther 1981;30:680-6.
128. Clark RF, Wei EM, Anderson PO. Meperidine: therapeutic use and toxicity. J Emerg Med 1995; 13:797-802.
129. Kronstrand R, Druid H, Holmgren P, et al. A cluster of fentanyl-related deaths among drug addicts in Sweden. Forensic Sci Int 1997;88: 185-93.
130. Martin M, Hecker J, Clark R, et al. China White epidemic: an eastern United States emergency department experience. Ann Emerg Med 1991; 20:158-64.
131. Meuldermans W, Hendrickx J, Lauwers W, et al. Excretion and biotransformation of alfentanil and sufentanil in rats and dogs. Drug Metab Disposition 1987;15:905-13.
132. Meuldermans W, Van Peer A, Hendrickx J, et al. Alfentanil pharmacokinetics and metabolism in humans. Anesthesiology 1988;69:527-34.
133. Silverstein JH, Rieders MF, McMullin M, et al. An analysis of the duration of fentanyl and its metabolites in urine and saliva. Anesth Analg 1993;76:618-21.
134. Feierman DE. Identification of cytochrome P450 3A1/2 as the major P450 isoform responsible for the metabolism of fentanyl by rat liver microsomes. Anesth Analg 1996;82:936-41.
135. Labroo RB, Paine MF, Thummel KE, et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4; implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Disposition 1997;25:1072-80.
136. Tateishi T, Wood AJ, Guengerich FP, et al. Biotransformation of tritiated fentanyl in human liver microsome, monitoring metabolism using phenylacetic acid and 2-phenylethanol. Biochem Pharmacol 1995;50:1921-4.
137. Yun CH, Wood M, Wood AJ, et al. Identification of the pharmacogenetic determinants of altentanil metabolism: cytochrome P-450 3A4: an explanation of the variable elimination clearance. Anesthesiology 1992;77:467-74.
138. Guitton J, Buronfosse T, Desage M, et al. Possible involvement of multiple cytochrome P450s in fentanyl and sufentanil metabolism as opposed to alfentanil. Biochem Pharmacol 1997;53: 1613-19.
139. Holsztynska EJ, Domino EF. Biotransformation of phencyclidine. Drug Metab Rev 1985/86;16: 285-20.
140. Kammerer RC, Cho, AK. The biotransformation of phencyclidine. In: Domino EF, editor. PCP (Phencyclidine): Historical and Current Perspectives. Ann Arbor, MI: NPP Books, 1986;177-89.
141. Cook CE, Jeffcoat AR, Perez-Reyes M. Pharmacokinetic studies of cocaine and phencyclidine in man. In: Barnett G, Chiang CN, editors. Pharmacokineties and Pharmacodynamics of Psychoactive Drugs. Foster City, CA: Biomedical Publications, 1985;48-74.
142. Laurenzana EM, Owens SM. Brain microsomal metabolism of phencyclidine in male and female rats. Brain Res 1997;756:256-65.
143. Holsztynska FJ, Weber WW, Domino EF. Genetic polymorphism of cytochrome P-450-dependent phencyclidine hydroxylation in mice: comparison to phemcyclidine hydroxylation in humans. Drug Metab Disposition 1991;19:48-53.
144. Laurenzana EM, Owens SM. Metabolism of phencyclidinc by human liver microsomes. Drug Metab Disposition 1997;25:557-63.
145. Ho IK, Onoda KI, Flin BA. Effects of chronic administration of phencyclidine on hepatic mixed-function oxidases in the mouse. Biochem Pharmacol 1981;30:545-7.
146. Hiratsuka A, Chu TYY, Di Stefano EW, et al. Inactivation of constitutive hepatic cytochromes P450 by phencyclidine in the rat. Drug Metab Disposition 1995;23:201-6.
147. Law FCP, Hall GH, Carruthers DR. Tissue distribution, biliary excretion, and irreversible binding of 14C PCP derived radioactivity in the rat. Fed Proc 1979;38:264.
148. Hoag MK, Trevor AJ, Asscher Y, et al. Metabolism-dependent inactivation of liver microsomeal enzymes by phencyclidine. Drug Metab Disposition 1984;12:371-5.
149. Ward D, Trevor AJ, Adams JD, et al. Metabolism of phencyclidine: the role of iminium ion formation in covalent binding to rabbit microsomal protein. Drug Metab Disposition 1982;10: 690-5.
150. Brady JF, Dokko J, DiStefano EW, et al. Mechanism-based inhibition of cytochrome P-450 by heterocyclic analogues of phencyclidine. Drug Metab Disposition 1987;15:648-52.
151. Osawa Y, Coon M. Selective mechanism-based inactivation of the major phenobarbital-inducible P-450 cytochrome from rabbit liver by phencyclidine and its oxidation product, the iminium compound. Drug Metab Disposition 1989;17: 7-13.
152. Crowley JR, Hollenberg PF. Mechanism-based inactivation of rat liver cytochrome P4502B1 by phencyclidine and its oxidative product, the iminium ion. Drug Metabolism and Disposition 1995;23:786-93.
153. Sharma U, Roberts ES, Kent UM, et al. Metabolic inactivation of cytochrome P4502B1 by phencyclidine: immunochemical and radiochemical analyses of the protective effects of glutathione. Drug Metab Disposition 1997;25: 243-50.
154. Owens SM, Gunnel M, Laurenzana EM, et al. Dose- and time-dependent changes in phencyclidine metabolite covalent binding in rats and the possible role of CYP2D1. J Pharmacol Exp Ther 1993;265:1261-6.
155. Shelnutt SR, Badger TM, Owens SM. Phencyclidine metabolite irreversible binding in the rat: gonadal steroid regulation and CYP2C11. J Pharmacol Exp Ther 1996;277:292-8.